If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
341
results.
Updated on
15/11/2026 [08:23:00]
Results 50 to 75 of 341
Absstract of: US20260337666A1
The present invention provides methods of profiling gene and protein expression of a plurality of nuclei from a single cell type and comparing the profiles to determine variability among cell populations, samples from different subjects, and cells expressing a disease phenotype.
Absstract of: US20260338793A1
0000 A method for treating sarcopenia. The method involves measuring a protein or mRNA level of asporin, PADI2, adenosine 5′-monophosphoramidase HINT2, or HSDL2 in a biological sample isolated from a subject. The subject is diagnosed as having sarcopenia by comparing the protein or mRNA level of the subject measured with that of a control group, where the subject is diagnosed with sarcopenia when the protein or mRNA level of asporin or PADI2 in the subject is increased compared to that of the control group, or when the protein or mRNA level of adenosine 5′-monophosphoramidase HINT2 or HSDL2 in the subject is decreased compared to that of the control group. The subject diagnosed with sarcopenia is then treated.
Absstract of: US20260337275A1
Provided herein are methods and compositions that block Integrin Subunit beta 8 (ITGB8, also known as integrin αvβ8) to treat neurodegenerative diseases associated with microglial impairment including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).
Absstract of: US20260338803A1
A method of detecting, predicting or monitoring the progress of amyloid angiopathy, ARIA (amyloid-related imaging abnormalities) or CAA (cerebral amyloid angiopathy) in an individual. The method comprises the step of: determining the presence or quantity of an Aβ protein fragment in a biological sample obtained from the individual, wherein the Aβ protein fragment is an Aβ1-40 or Aβx-34 fragment or a fragment of Aβ1-40.
Absstract of: US20260338802A1
The invention relates to methods of detecting, diagnosing or monitoring an inflammatory condition of the central nervous system, in particular by detecting or measuring neutrophil extracellular traps, extracellular traps and/or cell free nucleosomes.
Absstract of: WO2026224399A1
A murine model for studying a neurological disorder A mouse model for monitoring disease progression of a neurological disorder, optionally when said disorder is associated with motor neuron degeneration in a subject. A method producing a model mouse comprising administering a non-transgenic mouse with circulatory extracellular vesicles isolated from the serum of a patient having a neurological disorder, preferably ALS. Also, a method for tracking the efficacy of a therapeutic agent for a neurological disorder comprising administering a therapeutic agent to the mouse model; measuring the one or more of markers for motor neuron activity and/or neuromuscular function; comparing the results of to those of an untreated mouse control.
Absstract of: WO2026223726A1
Provided are a polypeptide specifically binding to transferrin receptor 1 (TfR1) and a use thereof. The amino acid sequence of the polypeptide includes an amino acid sequence shown in SEQ ID No. 1 or an amino acid sequence having substitutions, additions, deletions and/or insertions at 1-15 amino acid residues in the amino acid sequence of SEQ ID No. 1. Experiments have demonstrated that the polypeptide has relatively strong ability to bind to TfR1 and can be used for disease diagnosis, treatment and drug delivery targeting TfR1.
Absstract of: WO2026227082A1
Methods of differentiating and quantifying modifications in the tau protein in bio-fluids to detect, classify, and treat a plurality of tauopathies are disclosed. Differentiating and quantifying the modifications in the tau protein are performed by isolating and quantifying 4R-tau peptides such as Microtubule Binding Region (MTBR)-tau275 peptides or MTBR-tau282 peptides, and an amount of 3R-tau peptides comprising MTBR-tau306 peptides from the plurality of tau proteins of the CSF sample.
Absstract of: WO2026225845A1
The present invention relates to an NK cell sensitivity cell surface expression factor of damaged neurons, and use thereof. Specifically, provided is a technique for identifying an NK cell sensitivity factor specifically expressed on damaged neurons and using same for the diagnosis and treatment of nerve damage. The expression factor of the present invention can be used as a marker for early diagnosis of nerve damage, and can also be applied to therapeutic strategies for neurological diseases, including the development of CAR-NK cell therapeutic agents.
Absstract of: WO2026227062A1
Provided herein are antigens for making antibodies that detect pT81 and T81 of α-synuclein, methods of making antibodies, antibodies, methods of using the antibodies to detect pT81 and T81 forms of α-synuclein, and uses thereof in diagnosis of diseases and disorders associated with pT81 such as Multiple Systems Atrophy (MSA).
Absstract of: JP2026174325A
0001 【課題】本発明は、免疫測定において高いＳ／Ｎ比をもたらす検体希釈用液の提供を目的の一つとする。 【解決手段】本発明は、検体中の検出対象タンパク質を検出するための免疫測定法において使用される検体希釈用液であって、無機塩を含有し、電気伝導度が１～３０ｍＳ／ｃｍである、検体希釈用液に関する。 【選択図】なし
Absstract of: WO2026224877A1
The purpose of the present invention is to provide novel technology for trapping cells and/or extracellular vesicles (EV) without using antibodies. The present invention is a solid phase carrier that has the ability to adsorb cells and/or extracellular vesicles and contains a substrate and an ion exchanger.
Absstract of: US20260338755A1
Rapid and accurate detection of personal exposure to or contamination with OP pesticides is critical to both research and clinical care for victims. However, this detection remains highly variable across commercially available assays, e.g., the Ellman method, and such assays may also not adequately detect low but clinically relevant levels of exposure biomarkers. Moreover, these assays are generally performed in the centralized laboratories, and is slow and expensive. These deficits translate into missed opportunities for the timely initiation of the most appropriate treatment and interventions for acutely or chronically poisoned victims. A simple, rapid, non-or minimally invasive biomonitoring tool for onsite sensitive and accurate detection of personal exposure to or contamination with OP pesticides is provided.
Absstract of: WO2026226814A1
Methods, kits, and systems for detecting cancer are disclosed. The methods involve isolating non-vesicular particles from a sample of a subject using a capture agent specific for a first biomarker associated with the particles. The isolated non-vesicular particles are then analyzed to detect the co-localization of a second biomarker and a third biomarker associated with the same individual particles. The biomarkers may include proteins, nucleic acids, lipids, or carbohydrates associated with the non-vesicular particles. Detection of particles displaying co-localization of the biomarkers may be correlated with the presence of cancer in the subject, providing a basis for cancer screening, diagnosis, or monitoring. Kits containing reagents and systems to perform these methods are also described.
Absstract of: WO2026227025A1
Provided are compositions and methods for high-throughput identification of peptide- MHC class I binding. An engineered cell having knockouts of HLA-A, HLA-B, HLA-C, TAPI, TAP2, and B2M, and optionally a serine recombinase landing pad, is transfected with a barcoded pcptidc-HLA library. Stable peptide- HLA complexes arc displayed on the cell surface and recruit RNA barcodes to secreted particles via a receptor binding domain. Comparison of barcode abundance in cells versus secreted particles identifies peptide- HLA combinations that form stable complexes, enabling epitope discovery across diverse HLA alleles for vaccine and immunotherapy applications.
Absstract of: US20260335261A1
Pharmaceutical compositions of colchicine for once-daily oral administration are provided for use in the treatment of chronic inflammation, including inflammation arising after COVID-19 vaccination and/or COVID-19 infection (Long COVID). The formulations comprise, in some embodiments, an immediate-release component and/or a sustained-release component, which is tailored to achieve a desired pharmacokinetic profile suitable for long-term anti-inflammatory therapy. The disclosed compositions are designed to reduce systemic levels of key inflammatory biomarkers, such as high-sensitivity C-reactive protein (hs-CRP), C-reactive protein (CRP), interleukin-1 (IL-1), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and myeloperoxidase (MPO), and to alleviate clinical manifestations of persistent inflammation, including vaccine-associated myocarditis, pericarditis, or other inflammatory sequelae. Methods of treating post-vaccination and/or post-infection inflammatory syndromes, improving quality of life, and reducing hospitalization risk in mammalian subjects are also provided.
Absstract of: WO2026226519A1
Disclosed are methods of assessing apolipoprotein ("APOE") genotype based on multiple parallel assays. The assays allow for comparison of relative amounts of ApoE isoforms in patient samples to quickly determine relative isoform values without need of reference to calibrators. The methods further allow for diagnosis and/or risk assessment of a subject's likelihood of developing a neurodegenerative disease, such as Alzheimer's disease or suffering Amyloid-Related Imaging Abnormalities (ARIA) as a function of treatment for a neurodegenerative disease.
Absstract of: US20260337565A1
The present disclosure relates in some aspects to methods, cells, and compositions for preparing isolated engineered immune cells comprising T cell receptors (TCRs) capable of recognizing a disease-associated antigen. In some aspects, the immune cells are T cells for use in immunotherapy. Provided In an embodiment are T cell preparation methods, including isolation, processing, incubation, and genetic engineering of cells and populations of cells. Also provided are the isolated engineered T cells and compositions produced by the methods in the present disclosure. In some aspects, the methods prepare T cells for adoptive therapy. In an embodiment, the disease-associated antigen is a cancer-associated antigen.
Absstract of: WO2025083068A1
The present invention relates to methods for capturing nucleic acid sequences while keeping/preserving their epigenetic information, preferably for capturing certain regions of the genome, thereby enriching these regions, while maintaining it epigenetic information, with the same probability/efficiency, independently of whether one or more nucleotides are epigenetically modified. In particular, the present invention relates to a method comprising the steps of: (i) providing a plurality of nucleic acid molecules, wherein each of the nucleic acid molecules comprises two regions: a first region and a second region, wherein the base identities in the first and second region both provide, independently, information on the base identities in the corresponding loci of one or more original nucleic acid molecules, wherein the first and the second regions in each of the molecules provided in (i) comprise at least one nucleotide at a position corresponding to the same locus in a region of interest, wherein that locus in the region of interest is occupied by a nucleotide susceptible of being modified; wherein at least two of the nucleic acid molecules of the plurality of nucleic acid molecules may have a different nucleotide in the first region at least at one position corresponding to the same locus in the region of interest, wherein that locus in the region of interest is occupied by a nucleotide susceptible of being modified and wherein, in the second region, a position corresponding
Absstract of: US20260337258A1
Described herein are anti-alpha-synuclein antibodies. More specifically, described herein are antibodies specific to serine 129 phosphorylated alpha-synuclein. Further described herein is the use of the anti alpha-synuclein antibodies for the treatment or diagnosis of a synucleinopathy. Further described are kits and compositions comprising the anti alpha-synuclein antibodies detecting alpha-synuclein in a sample.
Absstract of: AU2026253892A1
Abstract Compositions and kits for diagnosing and prognosing Alzheimer’s Disease (AD) in a human patient include a binding agent such as a monoclonal antibody for a biomarker conjugated to a detectable moiety such as a fluorophore, wherein the biomarker is chosen from CD163, CD91, CD59, MerTK and other phagocytosis- related molecules. Further compositions and kits employ panels of fluorophore- conjugated monoclonal antibodies for biomarkers including scavenger receptors. Methods for determining the relative expression of biomarkers, diagnosing AD, and determining the efficacy of AD therapeutic candidates such as phagocytosis- promoting agents and scavenger receptor agonists also appear. ct b s t r a c t c t
Absstract of: EP4830718A2
0001 Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.
Absstract of: WO2025137532A1
Disclosed herein are methods of measuring amyloid β protofibril levels in biological samples. Methods disclosed herein may detect amyloid β protofibril at femtomolar concentrations and selectively measure protofibril as compared to amyloid β monomers.
Absstract of: WO2025137077A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function and/or quality of life.
Nº publicación: EP4830807A2 28/10/2026
Applicant:
QUEST DIAGNOSTICS INVEST LLC [US]
Quest Diagnostics Investments LLC
Absstract of: EP4830807A2
0001 Provided are methods for the detection or quantitation of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (Aβ42) to amyloid beta 40 (Aβ40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
BOPI
Electronic site
